相关实验视频
Updated: Jul 10, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
IL12/23 作为免疫相关皮肤不良事件的治疗方法,使用乌斯特基努马布进行阻塞
Stephanie L Gu1,2, Tara Maier1, Andrea P Moy3
1Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.
Pharmaceuticals (Basel, Switzerland)
|November 25, 2023
概括
在癌症患者中,乌斯特基努马布有效治疗与免疫相关的牛皮型/利切诺型不良事件,超过70%的患者表现出积极反应. 这种治疗允许一些患者恢复检查点抑制剂治疗,而不会出现新的安全问题.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 与免疫相关的皮肤不良事件 (ircAEs) 是免疫检查点抑制剂的常见副作用,影响患者的生活质量和治疗连续性.
- 牛皮型和状IrcAEs与牛皮有相似之处,这表明IL-12/23通路抑制剂可能发挥作用.
- 作为一种IL-12/23抑制剂的乌斯特基努马布 (Ustekinumab) 正在被探索为这些特定的ircAEs的治疗选择.
研究的目的:
- 评估乌斯特基努马布在管理与免疫相关的牛皮形/形皮肤不良事件方面的疗效和安全性.
- 评估乌斯特基努马布对检查点抑制剂治疗延续和再试剂的反应率和影响.
主要方法:
- 纪念斯隆·凯特林癌症中心对14名患者进行了回顾性审查,这些患者接受了乌斯特基努马布治疗,以治疗牛皮形/利切诺इडIrcAEs.
- 响应分类包括完整的皮肤反应 (CcR),部分皮肤反应 (PcR) 和没有皮肤反应 (NcR).
- 分析实验室数据和组织病理学发现;评估与ustekinumab相关的不良事件.
主要成果:
- 14名患者中有10名 (71.4%) 对乌斯特基努马布有积极反应,60%的患者完全恢复.
- 乌斯特基努马布治疗促进了检查点抑制剂在6名患者中的2名患者的复发,这些患者之前由于ircAEs中断了治疗.
- 组织病理学揭示了接口或牛皮形皮炎;没有报告与ustekinumab相关的不良事件.
结论:
- 乌斯特基努马布在患有牛皮型/利切诺型免疫相关皮肤不良事件的小组患者中显示出治疗效益.
- 治疗耐受性很好,没有发现安全信号.
- 需要进一步的前性随机对照试验来验证这些发现.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145

